Ranibizumab biosimilar (Oceva) – real-world experience from India (RORE study)
The preliminary real-world data from this limited early series suggest that ranibizumab biosimilar (Oceva) appears to be efficacious and safe across the approved indications. However, long-term data with a larger population are needed to further strengthen the findings of this study.
Authors
- Chitaranjan Mishra
- Ashish Sharma (ORCID: https://orcid.org/0000-0002-8550-9791)
- Surendar S. Purohit
- Debdulal Chakraborty (ORCID: https://orcid.org/0000-0001-9693-7882)
- Jay Sheth
- Bhagyashree Meshram
Institutions
- Aditya Jyot Eye Hospital (IN)
- Eye Care Associates (US)
- Lotus Clinical Research (US)
- Electrovaya (Canada) (CA)
Publication Details
- Journal
- Expert Opinion on Biological Therapy
- Published
- 2025-12-02
- DOI
- https://doi.org/10.1080/14712598.2025.2606897
- Citations
- 1
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.80